论文信息 - A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. - 字舞流文

A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy.

M. Wirth | H. Lannert | S. Zastrow | M. Laniado | T. Gil | A. Heidenreich | J. Gschwend | M. Zühlsdorf | J. Gerloff | G. Mordenti | W. Uhl | M. Zühlsdorf